Pharmaceutical

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys and significantly impacts their quality of life. However, there is hope on the horizon, thanks to ongoing research and development efforts in the field of DMD drugs. This blog post will delve into the current landscape of the DMD drugs market, highlighting recent advancements, challenges, and the promising future of treatments for this debilitating condition. Understanding Duchenne Muscular Dystrophy: DMD is caused by mutations in the DMD gene, leading to the absence of dystrophin, a protein essential for muscle function. Without dystrophin, muscle cells become damaged and eventually die, leading to muscle weakness and loss of mobility. DMD is a progressive disease, and patients often lose the ability to walk by their early teens. Respiratory and cardiac complications further reduce life expectancy. Recent Advancements in DMD Drugs: ...